Cargando…

Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche

Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can...

Descripción completa

Detalles Bibliográficos
Autor principal: Chung, Kian Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488697/
https://www.ncbi.nlm.nih.gov/pubmed/28954768
http://dx.doi.org/10.1183/16000617.0064-2017
_version_ 1784792716073238528
author Chung, Kian Fan
author_facet Chung, Kian Fan
author_sort Chung, Kian Fan
collection PubMed
description Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies – the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off – it is already here, but we need more tools and implements to carry it out for the benefit of our patients.
format Online
Article
Text
id pubmed-9488697
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-94886972022-11-14 Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche Chung, Kian Fan Eur Respir Rev Series Asthma is a heterogeneous disease comprising several phenotypes driven by different pathways. To define these phenotypes or endotypes (phenotypes defined by mechanisms), an unbiased approach to clustering of various omics platforms will yield molecular phenotypes from which composite biomarkers can be obtained. Biomarkers can help differentiate between these phenotypes and pinpoint patients suitable for specific targeted therapies – the basis for personalised medicine. Biomarkers need to be linked to point-of-care biomarkers that may be measured readily in exhaled breath, blood or urine. The potential for using mobile healthcare approaches will help patient enpowerment, an essential tool for personalised medicine. Personalised medicine in asthma is not far off – it is already here, but we need more tools and implements to carry it out for the benefit of our patients. European Respiratory Society 2017-09-27 /pmc/articles/PMC9488697/ /pubmed/28954768 http://dx.doi.org/10.1183/16000617.0064-2017 Text en Copyright ©ERS 2017. https://creativecommons.org/licenses/by-nc/4.0/ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Series
Chung, Kian Fan
Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title_full Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title_fullStr Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title_full_unstemmed Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title_short Personalised medicine in asthma: time for action: Number 1 in the Series “Personalised medicine in respiratory diseases” Edited by Renaud Louis and Nicolas Roche
title_sort personalised medicine in asthma: time for action: number 1 in the series “personalised medicine in respiratory diseases” edited by renaud louis and nicolas roche
topic Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488697/
https://www.ncbi.nlm.nih.gov/pubmed/28954768
http://dx.doi.org/10.1183/16000617.0064-2017
work_keys_str_mv AT chungkianfan personalisedmedicineinasthmatimeforactionnumber1intheseriespersonalisedmedicineinrespiratorydiseaseseditedbyrenaudlouisandnicolasroche